^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CTM-N2D

    i
    Other names: CTM-N2D, Haplo/ allogeneic NKG2DL-targetting chimeric antigen receptor-grafted γδ T cell therapy, Haploidentical/ allogeneic natural killer group 2D ligand CAR-γδT cell therapy, NKG2DL-targetting chimeric antigen receptor-grafted gamma delta T cell therapy, Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell, CTMN2D, CTM N2D
    Associations

    News

    Trials
    Company:
    CytoMed Therap
    Drug class:
    γδ TCR modulator, NKG2DL-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1m
    Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) (clinicaltrials.gov)
    P1, N=12, Recruiting, CytoMed Therapeutics Pte Ltd | Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Mar 2023 --> Nov 2025
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    NKG2D (killer cell lectin like receptor K1)
    |
    CTM-N2D
    over2years
    ANGELICA: Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, CytoMed Therapeutics Pte Ltd
    New P1 trial
    |
    NKG2D (killer cell lectin like receptor K1)
    |
    CTM-N2D